FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800004342> ?p ?o ?g. }

• W2800004342 endingPage "2463" @default.
• W2800004342 startingPage "2452" @default.
• W2800004342 abstract "Abstract Purpose: One third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need. Here, we identify a specific posttranslational modification that occurs during endocrine resistance and which results in tumor susceptibility to the apoptosis-inducer TRAIL. This potentially offers a novel stratified approach to targeting endocrine-resistant breast cancer. Experimental Design: Cell line and primary-derived xenograft models of endocrine resistance were investigated for susceptibility to TRAIL. Tumor viability, cancer stem cell (CSC) viability (tumorspheres), tumor growth kinetics, and metastatic burden were assessed. Western blots for the TRAIL-pathway inhibitor, c-FLIP, and upstream regulators were performed. Results were confirmed in primary culture of 26 endocrine-resistant and endocrine-naïve breast tumors. Results: Breast cancer cell lines with acquired resistance to tamoxifen (TAMR) or faslodex were more sensitive to TRAIL than their endocrine-sensitive controls. Moreover, TRAIL eliminated CSC-like activity in TAMR cells, resulting in prolonged remission of xenografts in vivo. In primary culture, TRAIL significantly depleted CSCs in 85% endocrine-resistant, compared with 8% endocrine-naïve, tumors, whereas systemic administration of TRAIL in endocrine-resistant patient-derived xenografts reduced tumor growth, CSC-like activity, and metastases. Acquired TRAIL sensitivity correlated with a reduction in intracellular levels of c-FLIP, and an increase in Jnk-mediated phosphorylation of E3-ligase, ITCH, which degrades c-FLIP. Conclusions: These results identify a novel mechanism of acquired vulnerability to an extrinsic cell death stimulus, in endocrine-resistant breast cancers, which has both therapeutic and prognostic potential. Clin Cancer Res; 24(10); 2452–63. ©2018 AACR." @default.
• W2800004342 created "2018-05-17" @default.
• W2800004342 creator A5000454845 @default.
• W2800004342 creator A5008441610 @default.
• W2800004342 creator A5012364827 @default.
• W2800004342 creator A5015081490 @default.
• W2800004342 creator A5021408309 @default.
• W2800004342 creator A5023545324 @default.
• W2800004342 creator A5028758526 @default.
• W2800004342 creator A5028884075 @default.
• W2800004342 creator A5054292350 @default.
• W2800004342 creator A5057403437 @default.
• W2800004342 creator A5065587850 @default.
• W2800004342 creator A5073495103 @default.
• W2800004342 creator A5082643230 @default.
• W2800004342 creator A5084823631 @default.
• W2800004342 creator A5085631179 @default.
• W2800004342 creator A5090207924 @default.
• W2800004342 creator A5091309671 @default.
• W2800004342 date "2018-05-14" @default.
• W2800004342 modified "2023-10-16" @default.
• W2800004342 title "Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP" @default.
• W2800004342 cites W1518987711 @default.
• W2800004342 cites W1810933484 @default.
• W2800004342 cites W1821522531 @default.
• W2800004342 cites W1919584830 @default.
• W2800004342 cites W1922475963 @default.
• W2800004342 cites W1961026612 @default.
• W2800004342 cites W1964304371 @default.
• W2800004342 cites W1976203623 @default.
• W2800004342 cites W1979067350 @default.
• W2800004342 cites W1980825754 @default.
• W2800004342 cites W1984345184 @default.
• W2800004342 cites W1988385815 @default.
• W2800004342 cites W1989598939 @default.
• W2800004342 cites W1990752073 @default.
• W2800004342 cites W1990841870 @default.
• W2800004342 cites W1991229228 @default.
• W2800004342 cites W1998233615 @default.
• W2800004342 cites W1998728654 @default.
• W2800004342 cites W2002514277 @default.
• W2800004342 cites W2013956549 @default.
• W2800004342 cites W2014001512 @default.
• W2800004342 cites W2016567163 @default.
• W2800004342 cites W2016626787 @default.
• W2800004342 cites W2018725927 @default.
• W2800004342 cites W2020651991 @default.
• W2800004342 cites W2023529679 @default.
• W2800004342 cites W2025005089 @default.
• W2800004342 cites W2030402878 @default.
• W2800004342 cites W2032563527 @default.
• W2800004342 cites W2033747658 @default.
• W2800004342 cites W2036673057 @default.
• W2800004342 cites W2036677192 @default.
• W2800004342 cites W2063331298 @default.
• W2800004342 cites W2065629669 @default.
• W2800004342 cites W2072787342 @default.
• W2800004342 cites W2078510083 @default.
• W2800004342 cites W2104264382 @default.
• W2800004342 cites W2105441981 @default.
• W2800004342 cites W2112252566 @default.
• W2800004342 cites W2112986537 @default.
• W2800004342 cites W2114765209 @default.
• W2800004342 cites W2115504447 @default.
• W2800004342 cites W2116937653 @default.
• W2800004342 cites W2117357260 @default.
• W2800004342 cites W2128347157 @default.
• W2800004342 cites W2137698996 @default.
• W2800004342 cites W2138832277 @default.
• W2800004342 cites W2141232624 @default.
• W2800004342 cites W2144790402 @default.
• W2800004342 cites W2151082560 @default.
• W2800004342 cites W2157995673 @default.
• W2800004342 cites W2158702480 @default.
• W2800004342 cites W2160064770 @default.
• W2800004342 cites W2163014794 @default.
• W2800004342 cites W2166355008 @default.
• W2800004342 cites W2167188058 @default.
• W2800004342 cites W2171139000 @default.
• W2800004342 cites W2206774775 @default.
• W2800004342 cites W2290145688 @default.
• W2800004342 cites W2343623791 @default.
• W2800004342 cites W2733695124 @default.
• W2800004342 cites W4206223302 @default.
• W2800004342 doi "https://doi.org/10.1158/1078-0432.ccr-17-1381" @default.
• W2800004342 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29363524" @default.
• W2800004342 hasPublicationYear "2018" @default.
• W2800004342 type Work @default.
• W2800004342 sameAs 2800004342 @default.
• W2800004342 citedByCount "29" @default.
• W2800004342 countsByYear W28000043422018 @default.
• W2800004342 countsByYear W28000043422019 @default.
• W2800004342 countsByYear W28000043422020 @default.
• W2800004342 countsByYear W28000043422021 @default.
• W2800004342 countsByYear W28000043422022 @default.
• W2800004342 countsByYear W28000043422023 @default.
• W2800004342 crossrefType "journal-article" @default.
• W2800004342 hasAuthorship W2800004342A5000454845 @default.

• next